{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T03:36:45Z","timestamp":1783741005960,"version":"3.55.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,3]]},"DOI":"10.7759\/cureus.87250","type":"journal-article","created":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T23:45:28Z","timestamp":1751586328000},"source":"Crossref","is-referenced-by-count":2,"title":["Efficacy of Low-Dose Fenfluramine on Adult Patients With Lennox-Gastaut Syndrome"],"prefix":"10.7759","author":[{"given":"Mutsuki","family":"Takeda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Kitazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Sonoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Morihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Miyaji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Higashiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuo","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naohisa","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Doi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumiaki","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.17241","article-title":"International League Against Epilepsy classification and definition of epilepsy syndromes with onset in childhood: position paper by the ILAE Task Force on Nosology and Definitions","volume":"63","author":"Specchio N","year":"2022","unstructured":"Specchio N, Wirrell EC, Scheffer IE, et al.. International League Against Epilepsy classification and definition of epilepsy syndromes with onset in childhood: position paper by the ILAE Task Force on Nosology and Definitions. Epilepsia. 2022, 63:1398-442. 10.1111\/epi.17241","journal-title":"Epilepsia"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.2000.tb00179.x","article-title":"Long-term seizure outcome in 74 patients with Lennox-Gastaut syndrome: effects of incorporating MRI head imaging in defining the cryptogenic subgroup","volume":"41","author":"Goldsmith IL","year":"2000","unstructured":"Goldsmith IL, Zupanc ML, Buchhalter JR. Long-term seizure outcome in 74 patients with Lennox-Gastaut syndrome: effects of incorporating MRI head imaging in defining the cryptogenic subgroup. Epilepsia. 2000, 41:395-9. 10.1111\/j.1528-1157.2000.tb00179.x","journal-title":"Epilepsia"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-017-3188-y","article-title":"Lennox-Gastaut syndrome: a comprehensive review","volume":"39","author":"Asadi-Pooya AA","year":"2018","unstructured":"Asadi-Pooya AA. Lennox-Gastaut syndrome: a comprehensive review. Neurol Sci. 2018, 39:403-14. 10.1007\/s10072-017-3188-y","journal-title":"Neurol Sci"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2011.03177.x","article-title":"Definition and natural history of Lennox-Gastaut syndrome","volume":"52 Suppl 5","author":"Camfield PR","year":"2011","unstructured":"Camfield PR. Definition and natural history of Lennox-Gastaut syndrome. Epilepsia. 2011, 52 Suppl 5:3-9. 10.1111\/j.1528-1167.2011.03177.x","journal-title":"Epilepsia"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1097\/00004691-200311000-00005","article-title":"Lennox-Gastaut syndrome (childhood epileptic encephalopathy)","volume":"20","author":"Markand ON","year":"2003","unstructured":"Markand ON. Lennox-Gastaut syndrome (childhood epileptic encephalopathy). J Clin Neurophysiol. 2003, 20:426-41. 10.1097\/00004691-200311000-00005","journal-title":"J Clin Neurophysiol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1989.tb05316.x","article-title":"Proposal for revised classification of epilepsies and epileptic syndromes. Commission on Classification and Terminology of the International League Against Epilepsy","volume":"30","year":"1989","unstructured":"Proposal for revised classification of epilepsies and epileptic syndromes. Commission on Classification and Terminology of the International League Against Epilepsy. Epilepsia. 1989, 30.389-99. 10.1111\/j.1528-1157.1989.tb05316.x","journal-title":"Epilepsia"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocn.2023.07.014","article-title":"The new International League Against Epilepsy (ILAE) definition of Lennox-Gastaut syndrome: practical implications and limitations","volume":"115","author":"Asadi-Pooya AA","year":"2023","unstructured":"Asadi-Pooya AA. The new International League Against Epilepsy (ILAE) definition of Lennox-Gastaut syndrome: practical implications and limitations. J Clin Neurosci. 2023, 115:43-6. 10.1016\/j.jocn.2023.07.014","journal-title":"J Clin Neurosci"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1212\/CPJ.0000000000000527","article-title":"Late-onset Lennox-Gastaut syndrome: diagnostic evaluation and outcome","volume":"8","author":"Smith KM","year":"2018","unstructured":"Smith KM, Britton JW, Cascino GD. Late-onset Lennox-Gastaut syndrome: diagnostic evaluation and outcome. Neurol Clin Pract. 2018, 8:397-402. 10.1212\/CPJ.0000000000000527","journal-title":"Neurol Clin Pract"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.2.5514.624","article-title":"Treatment of refractory obesity with fenfluramine","volume":"2","author":"Munro JF","year":"1966","unstructured":"Munro JF, Seaton DA, Duncan LJ. Treatment of refractory obesity with fenfluramine. Br Med J. 1966, 2:624-5. 10.1136\/bmj.2.5514.624","journal-title":"Br Med J"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198511283132219","article-title":"Treatment of self-induced photosensitive epilepsy with fenfluramine","volume":"313","author":"Aicardi J","year":"1985","unstructured":"Aicardi J, Gastaut H. Treatment of self-induced photosensitive epilepsy with fenfluramine. N Engl J Med. 1985, 313:1419. 10.1056\/NEJM198511283132219","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(76)90298-3","article-title":"Comparative action of fenfluramine on the uptake and release of serotonin and dopamine","volume":"35","author":"Kannengiesser MH","year":"1976","unstructured":"Kannengiesser MH, Hunt PF, Raynaud JP. Comparative action of fenfluramine on the uptake and release of serotonin and dopamine. Eur J Pharmacol. 1976, 35:35-43. 10.1016\/0014-2999(76)90298-3","journal-title":"Eur J Pharmacol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2013.331","article-title":"Evidence for a role of transporter-mediated currents in the depletion of brain serotonin induced by serotonin transporter substrates","volume":"39","author":"Baumann MH","year":"2014","unstructured":"Baumann MH, Bulling S, Benaderet TS, et al.. Evidence for a role of transporter-mediated currents in the depletion of brain serotonin induced by serotonin transporter substrates. Neuropsychopharmacology. 2014, 39:1355-65. 10.1038\/npp.2013.331","journal-title":"Neuropsychopharmacology"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-023-01881-w","article-title":"Fenfluramine: a review in Dravet and Lennox-Gastaut syndromes","volume":"83","author":"Frampton JE","year":"2023","unstructured":"Frampton JE. Fenfluramine: a review in Dravet and Lennox-Gastaut syndromes. Drugs. 2023, 83:923-34. 10.1007\/s40265-023-01881-w","journal-title":"Drugs"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1192022","article-title":"Fenfluramine: a plethora of mechanisms?","volume":"14","author":"Sourbron J","year":"2023","unstructured":"Sourbron J, Lagae L. Fenfluramine: a plethora of mechanisms?. Front Pharmacol. 2023, 14:1192022. 10.3389\/fphar.2023.1192022","journal-title":"Front Pharmacol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2020.106989","article-title":"Fenfluramine acts as a positive modulator of sigma-1 receptors","volume":"105","author":"Martin P","year":"2020","unstructured":"Martin P, de Witte PA, Maurice T, Gammaitoni A, Farfel G, Galer B. Fenfluramine acts as a positive modulator of sigma-1 receptors. Epilepsy Behav. 2020, 105:106989. 10.1016\/j.yebeh.2020.106989","journal-title":"Epilepsy Behav"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.102.23.2836","article-title":"Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications","volume":"102","author":"Rothman RB","year":"2000","unstructured":"Rothman RB, Baumann MH, Savage JE, Rauser L, McBride A, Hufeisen SJ, Roth BL. Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation. 2000, 102:2836-41. 10.1161\/01.cir.102.23.2836","journal-title":"Circulation"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199708283370901","article-title":"Valvular heart disease associated with fenfluramine-phentermine","volume":"337","author":"Connolly HM","year":"1997","unstructured":"Connolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS, Edwards WD, Schaff HV. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med. 1997, 337:581-8. 10.1056\/NEJM199708283370901","journal-title":"N Engl J Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1111\/ene.13195","article-title":"Low-dose fenfluramine significantly reduces seizure frequency in Dravet syndrome: a prospective study of a new cohort of patients","volume":"24","author":"Schoonjans A","year":"2017","unstructured":"Schoonjans A, Paelinck BP, Marchau F, et al.. Low-dose fenfluramine significantly reduces seizure frequency in Dravet syndrome: a prospective study of a new cohort of patients. Eur J Neurol. 2017, 24:309-14. 10.1111\/ene.13195","journal-title":"Eur J Neurol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32500-0","article-title":"Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial","volume":"394","author":"Lagae L","year":"2019","unstructured":"Lagae L, Sullivan J, Knupp K, et al.. Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial. Lancet. 2019, 394:2243-54. 10.1016\/S0140-6736(19)32500-0","journal-title":"Lancet"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2022.0829","article-title":"Efficacy and safety of fenfluramine for the treatment of seizures associated with Lennox-Gastaut syndrome: a randomized clinical trial","volume":"79","author":"Knupp KG","year":"2022","unstructured":"Knupp KG, Scheffer IE, Ceulemans B, et al.. Efficacy and safety of fenfluramine for the treatment of seizures associated with Lennox-Gastaut syndrome: a randomized clinical trial. JAMA Neurol. 2022, 79:554-64. 10.1001\/jamaneurol.2022.0829","journal-title":"JAMA Neurol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1111\/epi.17431","article-title":"Fenfluramine provides clinically meaningful reduction in frequency of drop seizures in patients with Lennox-Gastaut syndrome: Interim analysis of an open-label extension study","volume":"64","author":"Knupp KG","year":"2023","unstructured":"Knupp KG, Scheffer IE, Ceulemans B, et al.. Fenfluramine provides clinically meaningful reduction in frequency of drop seizures in patients with Lennox-Gastaut syndrome: Interim analysis of an open-label extension study. Epilepsia. 2023, 64:139-51. 10.1111\/epi.17431","journal-title":"Epilepsia"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebcr.2016.01.004","article-title":"Challenges in identifying Lennox-Gastaut syndrome in adults: A case series illustrating its changing nature","volume":"5","author":"Pi\u00f1a-Garza JE","year":"2016","unstructured":"Pi\u00f1a-Garza JE, Chung S, Montouris GD, Radtke RA, Resnick T, Wechsler RT. Challenges in identifying Lennox-Gastaut syndrome in adults: A case series illustrating its changing nature. Epilepsy Behav Case Rep. 2016, 5:38-43. 10.1016\/j.ebcr.2016.01.004","journal-title":"Epilepsy Behav Case Rep"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2024.1371704","article-title":"Optimal dose of fenfluramine in adjuvant treatment of drug-resistant epilepsy: evidence from randomized controlled trials","volume":"15","author":"Xu Y","year":"2024","unstructured":"Xu Y, Chen D, Liu L. Optimal dose of fenfluramine in adjuvant treatment of drug-resistant epilepsy: evidence from randomized controlled trials. Front Neurol. 2024, 15:1371704. 10.3389\/fneur.2024.1371704","journal-title":"Front Neurol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.00223","article-title":"Allosteric modulators of sigma-1 receptor: a review","volume":"10","author":"Vavers E","year":"2019","unstructured":"Vavers E, Zvejniece L, Maurice T, Dambrova M. Allosteric modulators of sigma-1 receptor: a review. Front Pharmacol. 2019, 10:223. 10.3389\/fphar.2019.00223","journal-title":"Front Pharmacol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1007\/s10309-023-00646-5","article-title":"Fenfluramine in clinical practice: new therapy option for Dravet and Lennox-Gastaut syndromes","volume":"37","author":"Muhle H","year":"2024","unstructured":"Muhle H, Kurlemann G, Lehmann I, et al.. Fenfluramine in clinical practice: new therapy option for Dravet and Lennox-Gastaut syndromes. Clin Epileptol. 2024, 37:68-78. 10.1007\/s10309-023-00646-5","journal-title":"Clin Epileptol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1080\/17460441.2021.1838483","article-title":"Bi-phasic dose response in the preclinical and clinical developments of sigma-1 receptor ligands for the treatment of neurodegenerative disorders","volume":"16","author":"Maurice T","year":"2021","unstructured":"Maurice T. Bi-phasic dose response in the preclinical and clinical developments of sigma-1 receptor ligands for the treatment of neurodegenerative disorders. Expert Opin Drug Discov. 2021, 16:373-89. 10.1080\/17460441.2021.1838483","journal-title":"Expert Opin Drug Discov"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(19)30148-6","article-title":"Dual antiplatelet therapy using cilostazol for secondary prevention in patients with high-risk ischaemic stroke in Japan: a multicentre, open-label, randomised controlled trial","volume":"6","author":"Toyoda K","year":"2019","unstructured":"Toyoda K, Uchiyama S, Yamaguchi T, et al.. Dual antiplatelet therapy using cilostazol for secondary prevention in patients with high-risk ischaemic stroke in Japan: a multicentre, open-label, randomised controlled trial. Lancet Neurol. 2019, 6:539-48. 10.1016\/S1474-4422(19)30148-6","journal-title":"Lancet Neurol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(99)00025-4","article-title":"Involvement of sigma receptors in the modulation of the glutamatergic\/NMDA neurotransmission in the dopaminergic systems","volume":"5","author":"Benjamin G","year":"1999","unstructured":"Benjamin G, Guy D. Involvement of sigma receptors in the modulation of the glutamatergic\/NMDA neurotransmission in the dopaminergic systems. Eur J Pharmacol. 1999, 5:183-96. 10.1016\/S0014-2999(99)00025-4","journal-title":"Eur J Pharmacol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebr.2024.100714","article-title":"Low-dose fenfluramine as an effective treatment option for 'atypical' Dravet syndrome","volume":"28","author":"Iguchi A","year":"2024","unstructured":"Iguchi A, Yamaguchi T, Yabe T, et al.. Low-dose fenfluramine as an effective treatment option for 'atypical' Dravet syndrome. Epilepsy Behav Rep. 2024, 28:100714. 10.1016\/j.ebr.2024.100714","journal-title":"Epilepsy Behav Rep"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2007.01072.x","article-title":"Long-term prognosis for symptomatic (secondarily) generalized epilepsies: a population-based study","volume":"48","author":"Camfield P","year":"2007","unstructured":"Camfield P, Camfield C. Long-term prognosis for symptomatic (secondarily) generalized epilepsies: a population-based study. Epilepsia. 2007, 48:1128-32. 10.1111\/j.1528-1167.2007.01072.x","journal-title":"Epilepsia"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2024.107406","article-title":"A systematic review of electroencephalographic findings in Lennox-Gastaut syndrome","volume":"205","author":"Nizami FM","year":"2024","unstructured":"Nizami FM, Trivedi S, Kalita J. A systematic review of electroencephalographic findings in Lennox-Gastaut syndrome. Epilepsy Res. 2024, 205:107406. 10.1016\/j.eplepsyres.2024.107406","journal-title":"Epilepsy Res"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1111\/epi.17414","article-title":"Paroxysmal fast activity is a biomarker of treatment response in deep brain stimulation for Lennox-Gastaut syndrome","volume":"63","author":"Dalic LJ","year":"2022","unstructured":"Dalic LJ, Warren AE, Spiegel C, Thevathasan W, Roten A, Bulluss KJ, Archer JS. Paroxysmal fast activity is a biomarker of treatment response in deep brain stimulation for Lennox-Gastaut syndrome. Epilepsia. 2022, 63:3134-47. 10.1111\/epi.17414","journal-title":"Epilepsia"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/369295-efficacy-of-low-dose-fenfluramine-on-adult-patients-with-lennox-gastaut-syndrome","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T23:45:28Z","timestamp":1751586328000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/369295-efficacy-of-low-dose-fenfluramine-on-adult-patients-with-lennox-gastaut-syndrome"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,3]]},"references-count":32,"URL":"https:\/\/doi.org\/10.7759\/cureus.87250","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7,3]]}}}